We're developing a robust portfolio of multiplex tests built on innovative exosome-based, disease-specific biomarker analysis.
These tests provide precise, early, and actionable insights, paving the way for personalized and transformative patient care.
We empower physicians with unparalleled insights to deliver earlier, more effective treatments.
Exosomes Make the Difference
Exosomes carry proteins, DNA, and RNA that originate from specific organs and tissues. Their disease-specific cargo evolves with the condition. Their lipid bilayer protects biomarkers from degradation in biofluids, ensuring stability over time. Additionally, biomarkers from exosomes can be much more concentrated as compared to direct blood-based markers, facilitating easier and more reproducible quantification.
The Impact of Severe Eye Disease
The incidence and prevalence of severe eye diseases increase as people age. Our initial focus is on patients with early- to intermediate-stage age-related macular degeneration (AMD) and diabetic retinopathy (DR)— the leading causes of blindness. People older than 50 and diabetic patients may be tested by primary care providers for early detection. Our multiplex biomarker panels assess the risk of progression to vision-threatening disease. For patients with late-stage AMD or DR, our tests help optimize medication dosing, frequency, and personalized treatment.
Unmet Clinical Need
ExOcular tests provide physicians with insights into patients at risk for vision-threatening diseases. Our tests enable personalized treatment decisions that may delay or prevent blindness while effectively monitoring intervention success.
Our Solution
